Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are tumours angiogenesis-dependent?

H M W Verheul1, E E Voest, R O Schlingemann

  • 1Department of Medical Oncology, University Medical Centre Utrecht, The Netherlands. h.m.w.verheul@azu.nl

The Journal of Pathology
|December 25, 2003
PubMed
Summary

Angiogenesis inhibitors show promise for cancer treatment, but clinical results lag behind preclinical findings. Human tumors exhibit complex, heterogeneous vascularization, requiring a nuanced approach to therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective evaluation of genomics-guided off-label treatment.

Nature·2026
Same author

The impact of immune checkpoint inhibitors on gonadal function in patients with solid tumors.

ESMO open·2025
Same author

Treatment and outcomes of local re-recurrence in rectal cancer: a multicentre observational cohort.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

Impact of whole genome sequencing on the care pathway for patients with cancer of unknown primary.

ESMO open·2025
Same author

Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2025
Same author

Authors response to Letter re: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) molecular complexity and response to targeted therapy.

ESMO open·2025

Area of Science:

  • Oncology
  • Vascular Biology
  • Cancer Therapeutics

Background:

  • Tumor growth and metastasis depend on new blood vessel formation (angiogenesis).
  • Preclinical studies strongly support tumor angiogenesis dependency.
  • Disappointing clinical outcomes have questioned this dependency due to immature tumor vasculature.

Purpose of the Study:

  • To evaluate the translation of angiogenesis inhibitors from preclinical cancer models to clinical application.
  • To summarize preclinical evidence for tumor angiogenesis dependency.
  • To explain discrepancies between preclinical expectations and clinical results.

Main Methods:

  • Review of preclinical in vivo experiments demonstrating tumor angiogenesis dependence.
  • Analysis of clinical trial results for angiogenesis inhibitors.
  • Evaluation of tumor vascular heterogeneity and its impact on treatment.

Main Results:

  • Preclinical models consistently show tumors require angiogenesis to grow and metastasize.
  • Clinical results with angiogenesis inhibitors have been less effective than anticipated.
  • Human tumors display significant heterogeneity in vascular architecture and function.

Conclusions:

  • Despite preclinical evidence, clinical efficacy of angiogenesis inhibitors is limited.
  • Human tumor angiogenesis is a complex, multifactorially regulated process.
  • Vascular immaturity in human tumors is a consequence of rapid, uncontrolled cell expansion.

Related Experiment Videos